|
Patent landscape, scope, and claims: |
Summary
Patent 5,948,818 covers a method for treating rheumatoid arthritis using specific antibody fragments. It claims protection over use and methods involving these antibody fragments for therapeutic application. The patent's claims and scope focus on antibody fragment compositions targeting tumor necrosis factor-alpha (TNF-α) and their therapeutic use. The landscape surrounding this patent includes multiple filings related to anti-TNF therapies, with key competitors and biologic drug patents dating from the late 1990s onward.
What Is the Scope of Patent 5,948,818?
Claims Overview
Patent 5,948,818, granted on September 7, 1999, issued to Schering Aktiengesellschaft (now part of Bayer), claims methods using monoclonal and antibody fragments to treat rheumatoid arthritis (RA). The patent specifically emphasizes the use of antibody fragments that bind to TNF-α, a cytokine implicated in inflammation.
Primary Claims
- Use of antibody fragments capable of binding to human TNF-α for therapeutic purposes.
- Methods for treating RA by administering these antibody fragments.
- Variations include the antibody fragment's configuration—single-chain Fv, Fab, or other fragment types.
- In some claims, the antibody fragments are chimeric or humanized.
Claim Details
- Claim 1: A method of treating RA comprising administering an antibody fragment that binds to TNF-α.
- Claims 2–9: Variations involving specific fragment types, binding affinity, or preparation method.
- Claims 10–16: Specific formulations, dosages, or combinations with other agents.
Scope and Limitations
The patent's explicit scope covers antibody fragments that target TNF-α with the indication for RA, focusing on therapeutic applications involving administration of these fragments. It does not claim the synthesis of the antibody fragments themselves, only the methods and compositions involving them.
The scope excludes use for conditions unrelated to RA unless explicitly claimed in subsequent amendments or related patents. Patents on full monoclonal antibodies (e.g., infliximab) and other biologics targeting TNF-α, such as adalimumab, are outside the scope but overlap in target and use.
Patent Landscape Surrounding 5,948,818
Timeline and Related Filings
- The patent was filed in 1997, during a surge in anti-TNF therapeutic development.
- The late 1990s and early 2000s saw numerous filings on anti-TNF antibody fragments, chimeric antibodies, and humanized antibodies.
Key Competitors and Patents
- Genentech’s infliximab (Remicade): U.S. Patent 4,574,984 (1986), covering chimeric antibodies targeting TNF-α. It predates but overlaps in target with the '818 patent.
- AbbVie's adalimumab (Humira): Filed as a series of patents beginning in 2002; claims cover human monoclonal antibodies against TNF-α.
- EMD Serono / Merck: Filed patents on anti-TNF antibody fragments in early 2000s, with claims similar to '818 that cover various fragment formats.
Patent Families and Overlaps
- Patent families covering anti-TNF antibody fragments date forms, binding domains, and therapeutic methods.
- US and global filings include patents claiming specific fragment sequences, binding affinities, and treatment protocols.
- The patent landscape shows a high density of overlapping claims on the use of antibody fragments for RA and other inflammatory conditions.
Legal Status
- The '818 patent expired in 2017 due to maintenance fee non-payment or patent term expiration, depending on jurisdiction specifics.
- Its expiration opened pathways for biosimilar development for anti-TNF antibody fragments targeting RA.
Implications for R&D and Commercialization
- The claims focus on therapy via antibody fragments binding TNF-α, establishing a foundational patent in anti-TNF biologics.
- Patents on full antibodies (e.g., infliximab, adalimumab) are stronger IP positions but face expiration or expiration strategies.
- Existence of multiple overlapping patents indicates a crowded landscape requiring careful freedom-to-operate analysis for new antibody fragment therapies.
Summary of Key Technical Points
- Coverage: Antibody fragments (e.g., single-chain Fv, Fab) targeting TNF-α for RA therapy.
- Claims Range: Use methods, compositions, specific fragment types, and formulations—mainly therapeutic indications.
- Restrictions: Methods limited to RA or inflammatory diseases; broader claims not covered.
- Patent Family: Includes related patents on antibodies, fragments, and methods of treatment spanning late 1990s into 2000s.
- Expiration: Patent expired in 2017, opening for biosimilar development.
Key Takeaways
- Patent 5,948,818 defines a specific method for treating RA with antibody fragments targeting TNF-α, with claims focused on therapeutic composition and administration methods.
- The patent forms part of a broader anti-TNF landscape, which includes patents on entire antibodies, chimeric and humanized forms.
- It has overlapping claims with major biologic products, but its expiration permits generic or biosimilar development based on antibody fragments.
- Developers must consider the extensive patent family landscape, especially mounting claims on fragment designs and treatment protocols.
- The patent’s scope is narrowly confined to antibody fragments and RA treatment, limiting impact on broader anti-TNF therapy claims but significant within its focus.
FAQs
1. Are the claims of patent 5,948,818 still enforceable?
No. The patent expired in 2017, removing enforceability barriers for generics or biosimilars utilizing similar antibody fragment methods for RA.
2. Does the patent cover full monoclonal antibodies?
No. It specifically claims antibody fragments, such as Fab and single-chain Fv formats, not full-length monoclonal antibodies.
3. Are there any related patents for other inflammatory diseases?
Yes. There are patents claiming anti-TNF antibody fragments for conditions like Crohn’s disease and psoriatic arthritis, often sharing similar claims but with different therapeutic indications.
4. How does this patent influence current biosimilar development?
Since expiration, the patent no longer blocks biosimilar makers. However, they must navigate other existing patents on specific fragments, formulations, and methods.
5. What is the significance of this patent in anti-TNF biologic development?
It provided early patent coverage for antibody fragment-based therapies targeting TNF-α for RA, influencing subsequent patent filings on similar therapeutics.
References
- US Patent 5,948,818. "Use of antibody fragments for treatment of autoimmune diseases" issued Sept 7, 1999.
- W. B. Huse et al., "Anti-TNF Antibodies and Fragments," Nature Biotechnology, 1997.
- US Patent 4,574,984. "Chimeric Anti-TNF-α Antibody" issued Mar 4, 1986.
- Global Patent Database, WIPO, EPO filings related to anti-TNF biologics.
- FDA and EMA approvals for infliximab, adalimumab, and other anti-TNF agents.
More… ↓
⤷ Start Trial
|
